KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Interest & Investment Income (2017 - 2022)

Historic Interest & Investment Income for Sarepta Therapeutics (SRPT) over the last 8 years, with Q4 2022 value amounting to $9.1 million.

  • Sarepta Therapeutics' Interest & Investment Income rose 950631.58% to $9.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $16.5 million, marking a year-over-year increase of 455762.71%. This contributed to the annual value of $36.3 million for FY2023, which is 11989.93% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Interest & Investment Income stood at $9.1 million for Q4 2022, which was up 950631.58% from $4.8 million recorded in Q3 2022.
  • Sarepta Therapeutics' 5-year Interest & Investment Income high stood at $9.1 million for Q4 2022, and its period low was -$7.0 million during Q3 2018.
  • Moreover, its 5-year median value for Interest & Investment Income was $160500.0 (2021), whereas its average is $403400.0.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first crashed by 388695.65% in 2018, then skyrocketed by 950631.58% in 2022.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Interest & Investment Income stood at -$2.3 million in 2018, then surged by 164.04% to $1.5 million in 2019, then tumbled by 95.2% to $71000.0 in 2020, then soared by 33.8% to $95000.0 in 2021, then skyrocketed by 9506.32% to $9.1 million in 2022.
  • Its last three reported values are $9.1 million in Q4 2022, $4.8 million for Q3 2022, and $2.4 million during Q2 2022.